Challenging the X-MAN: Horizon Discovery sign agreement with leading cancer pharma Milleni...


15-09-2008

Horizon Discovery (Horizon) today announced it has signed a commercial agreement with Millenium Pharmaceuticals Incorporated to broadly evaluate its X-MAN technology.

Cambridge, UK, September 15th 2008 – Horizon Discovery (Horizon) today announced it has signed a commercial agreement with Millenium Pharmaceuticals Incorporated to broadly evaluate its X-MAN technology.

X-MAN ‘Mutant And Normal’ human isogenic cell-lines are the first genetically-defined in vitro models of human cancer and their matched normal cell-types, that help accelerate and rationalize the discovery of novel ‘personalised’ medicines and their optimal assessment in clinical trials.

The agreement covers an eight month evaluation of a panel of seven X-MAN cell lines; including for the first time a set of double cancer-gene ‘knock-in’ lines designed to evaluate known mechanisms of patient resistance to targeted agents.  The lines under evaluation represent model genotypes of interest to Millenium; who will further characterize the lines and test known targeted agents against these genotypes as well as internally developed compounds.

“Chris Torrance, CEO of Horizon says “it is our aim to get our novel ‘patient-relevant’ X-MAN cancer models rapidly into the real world drug discovery arena and signing up Millenium to a comprehensive and expandable pilot programme will generate additional data on the ability of X-MAN cell lines to find novel ‘personalised’ cancer therapies”

Millenium will pay Horizon a six-figure fee and share key data-sets during the course of the evaluation period which will begin in October 2008.


About Horizon Discovery

Horizon Discovery is a translational genomics company founded in June 2007 and is headquartered at the Babraham Research Campus, Cambridge, UK and with additional research laboratories in Torino, Italy. Horizon’s goal is to convert new information on the genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery’s offering of isogenic cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds – a missing link in the rational and efficient development of novel targeted anti-cancer agents.

Contact: Dr Chris Torrance on +44 (0)1223 497360 or +44 (0)7739 825233

Web: www.horizondiscovery.com


 

Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation.

Horizon Discovery